News tagged with erlotinib

Related topics: lung cancer

Targeted therapies beneficial in KRAS-mutated NSCLC

(HealthDay)—Targeted therapies that do not contain erlotinib can be beneficial for patients with KRAS-mutated (KRAS mut+) advanced non-small-cell lung cancer (NSCLC), according to a study published online Aug. 1 in the ...

Aug 03, 2016
popularity2 comments 0

Erlotinib

Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed